Veterinary Anti-infectives Market

Executive Summary

Veterinary Anti-infectives Market was valued at US $0.30 billion in 2021 and is projected to grow at 8.19% CAGR over the forecast period to reach US $0.49 billion by 2027. Veterinary Anti-infectives Market represented US $0.04 billion opportunity over 2019-2021 and estimated to create US $0.18 billion opportunity in 2027 over 2021.

Veterinary Anti-infectives from Consainsights analyses the Veterinary Anti-infectives Market in the Life Sciences industry over the forecast period to 2027.

Veterinary Anti-infectives research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Veterinary Anti-infectives segmentation includes Animal Type, Product Type, Mode of Administration and Geography.

Based on the Animal Type, the Veterinary Anti-infectives analysis covers Cattle, Poultry, Cats, Dogs, Other Animals.

In Animal Type segment, Cattle segment has highest cagr growth of 7.25%.

Based on the Product Type, the Veterinary Anti-infectives analysis covers Antibacterial, Antivirals, Antifungals, Others.

In Product Type segment, Antibacterial segment has highest cagr growth of 7.25%.

Based on the Mode of Administration, the Veterinary Anti-infectives analysis covers Oral, Topical, Others.

In Mode of Administration segment, Oral segment has highest cagr growth of 7.25%.

Based on the region, the Veterinary Anti-infectives analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Bayer AG, Boehringer Ingelheim GmbH, Ceva Sante Animale, Elanco, Merck & Co Inc., Phibro Animal Health Corporation, Vetoquinol S.A., Virbac, Zoetis Inc. and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Animal Type

Introduction

In 2021, Cattle segment has the highest revenue of US $0.12 billion and is expected to grow at CAGR of 7.25% by 2027 Cattle segment has highest cagr growth of 7.25%.

Cattle

Cattle segment was valued at US $0.10 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.20 billion by 2027. Cattle segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

Poultry

Poultry segment was valued at US $0.06 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.12 billion by 2027. Poultry segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

Cats

Cats segment was valued at US $0.05 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.10 billion by 2027. Cats segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.04 billion opportunity in 2027 over 2021.

Dogs

Dogs segment was valued at US $0.02 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.03 billion by 2027. Dogs segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Other Animals

Other Animals segment was valued at US $0.02 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.04 billion by 2027. Other Animals segment represented US $0.00 billion opportunity over 2019-2021 and estimated to create US $0.01 billion opportunity in 2027 over 2021.

Product Type

Introduction

In 2021, Antibacterial segment has the highest revenue of US $0.11 billion and is expected to grow at CAGR of 7.25% by 2027 Antibacterial segment has highest cagr growth of 7.25%.

Antibacterial

Antibacterial segment was valued at US $0.09 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.18 billion by 2027. Antibacterial segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

Antivirals

Antivirals segment was valued at US $0.09 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.16 billion by 2027. Antivirals segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.06 billion opportunity in 2027 over 2021.

Antifungals

Antifungals segment was valued at US $0.04 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.07 billion by 2027. Antifungals segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.04 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.08 billion by 2027. Others segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.

Mode of Administration

Introduction

In 2021, Oral segment has the highest revenue of US $0.14 billion and is expected to grow at CAGR of 7.25% by 2027 Oral segment has highest cagr growth of 7.25%.

Oral

Oral segment was valued at US $0.12 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.22 billion by 2027. Oral segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.08 billion opportunity in 2027 over 2021.

Topical

Topical segment was valued at US $0.10 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.18 billion by 2027. Topical segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.05 billion in 2019 and is projected to grow at 7.25% CAGR over the forecast period to reach US $0.08 billion by 2027. Others segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.